[go: up one dir, main page]

MX2011011132A - Peptido auxiliar del antigeno del cancer. - Google Patents

Peptido auxiliar del antigeno del cancer.

Info

Publication number
MX2011011132A
MX2011011132A MX2011011132A MX2011011132A MX2011011132A MX 2011011132 A MX2011011132 A MX 2011011132A MX 2011011132 A MX2011011132 A MX 2011011132A MX 2011011132 A MX2011011132 A MX 2011011132A MX 2011011132 A MX2011011132 A MX 2011011132A
Authority
MX
Mexico
Prior art keywords
cancer antigen
helper peptide
antigen helper
peptide
induces
Prior art date
Application number
MX2011011132A
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of MX2011011132A publication Critical patent/MX2011011132A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/57525—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)

Abstract

La presente invención se refiere a un péptido de WT1 que tiene una secuencia de aminoácidos que consiste de aminoácidos contiguos derivados de una proteína WT1 e induce células T auxiliares específicas de WT1 por la unión de una molécula de MHC clase II, una composición farmacéutica que comprende las mismas y similares.
MX2011011132A 2009-04-23 2010-04-22 Peptido auxiliar del antigeno del cancer. MX2011011132A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009105286 2009-04-23
PCT/JP2010/057149 WO2010123065A1 (ja) 2009-04-23 2010-04-22 癌抗原ヘルパーペプチド

Publications (1)

Publication Number Publication Date
MX2011011132A true MX2011011132A (es) 2011-11-18

Family

ID=43011181

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011132A MX2011011132A (es) 2009-04-23 2010-04-22 Peptido auxiliar del antigeno del cancer.

Country Status (19)

Country Link
US (4) US9266932B2 (es)
EP (1) EP2423310B1 (es)
JP (2) JP5730191B2 (es)
KR (2) KR20170046192A (es)
CN (3) CN105622749B (es)
AR (1) AR076349A1 (es)
AU (1) AU2010240099B2 (es)
BR (1) BRPI1014998A2 (es)
CA (1) CA2757764C (es)
CO (1) CO6470802A2 (es)
DK (1) DK2423310T3 (es)
ES (1) ES2528766T3 (es)
IL (2) IL215668A0 (es)
MX (1) MX2011011132A (es)
NZ (1) NZ595707A (es)
SG (1) SG175178A1 (es)
TW (1) TWI517859B (es)
WO (1) WO2010123065A1 (es)
ZA (1) ZA201108336B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2071028E (pt) 2003-11-05 2012-04-10 Int Inst Cancer Immunology Inc Péptido antigénico de ligação a hla-dr derivado de wt1
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
WO2007120673A2 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
SI2119778T1 (sl) 2007-02-27 2016-03-31 International Institute Of Cancer Immunology, Inc. Postopek aktivacije celice T pomagalke in sestavek za uporabo postopka
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
CN103298928B (zh) 2010-10-05 2016-04-20 株式会社癌免疫研究所 用于激活辅助性t细胞的方法
EP2757373A4 (en) 2011-09-14 2015-07-01 Int Inst Cancer Immunology Inc METHOD OF MEASURING ANTI-WT1 ANTIBODIES
US20140341939A1 (en) * 2011-12-14 2014-11-20 National University Corporation Kochi University Modification of helper t cell-inducing polypeptide
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
CN110195040A (zh) * 2012-12-17 2019-09-03 大塚制药株式会社 辅助性t细胞的活化方法
PL2945647T3 (pl) 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenne peptydy wt-1 i sposoby ich zastosowania
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
RU2697443C2 (ru) * 2013-02-05 2019-08-14 Нитто Денко Корпорейшн Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения
RU2687026C2 (ru) * 2013-02-05 2019-05-06 Нитто Денко Корпорейшн Вакцинная композиция против злокачественной опухоли на основе пептида wt1 для мукозального введения
JP6512568B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
JP6512567B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
DK2982681T3 (en) 2013-03-29 2018-12-10 Sumitomo Dainippon Pharma Co Ltd WT1 ANTIGENPEPTIDKONJUGATVACCINE
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
KR101804343B1 (ko) 2014-02-26 2017-12-04 텔라 가부시키가이샤 Ｗｔ１ 항원성 폴리펩티드 및 상기 폴리펩티드를 포함하는 항종양제
CN106687129B (zh) * 2014-09-27 2021-07-20 大日本住友制药株式会社 注射用药物组合物
US10525096B2 (en) * 2014-12-11 2020-01-07 International Institute Of Cancer Immunology, Inc. Immunotherapy for angiogenic disease
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
US11419895B2 (en) * 2017-05-31 2022-08-23 Crage Medical Co., Limited Compositions and methods of cellular immunotherapy
MY182816A (en) * 2018-02-15 2021-02-05 National Univ Corporation Asahikawa Medical Univ Cancer antigen peptide
MX2021003660A (es) 2018-09-28 2021-05-28 Sumitomo Pharma Co Ltd Composicion inyectable.
CN115867303A (zh) 2020-05-12 2023-03-28 住友制药株式会社 用于治疗癌症的药物组合物
JPWO2023017836A1 (es) 2021-08-12 2023-02-16

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
JPH08289780A (ja) 1995-04-20 1996-11-05 Japan Organo Co Ltd 微生物等の検出方法、この検出方法に用いる抗体、及びこの抗体を産生する新規ハイブリドーマ
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030215458A1 (en) 1998-09-30 2003-11-20 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
KR100752065B1 (ko) 1998-09-30 2007-08-28 코릭사 코포레이션 Ｗｔ1 특이적 면역요법용 조성물 및 방법
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
AU7859900A (en) 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
EP1460898A4 (en) * 2002-01-03 2006-05-24 Univ Texas WT1 ANTISENSE OLIGOS FOR THE INHIBITION OF BREAST CANCER
US7312243B1 (en) * 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
PT2071028E (pt) 2003-11-05 2012-04-10 Int Inst Cancer Immunology Inc Péptido antigénico de ligação a hla-dr derivado de wt1
WO2007047764A2 (en) * 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
US8470976B2 (en) * 2006-06-17 2013-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting macromolecules into the nucleus
US8617531B2 (en) * 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
SI2119778T1 (sl) * 2007-02-27 2016-03-31 International Institute Of Cancer Immunology, Inc. Postopek aktivacije celice T pomagalke in sestavek za uporabo postopka
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
CN103298928B (zh) 2010-10-05 2016-04-20 株式会社癌免疫研究所 用于激活辅助性t细胞的方法
US10525096B2 (en) 2014-12-11 2020-01-07 International Institute Of Cancer Immunology, Inc. Immunotherapy for angiogenic disease

Also Published As

Publication number Publication date
EP2423310A4 (en) 2012-11-14
JP2015177799A (ja) 2015-10-08
CN113045636A (zh) 2021-06-29
CA2757764A1 (en) 2010-10-28
JP6145475B2 (ja) 2017-06-14
CN105622749B (zh) 2021-03-09
RU2011147479A (ru) 2013-05-27
CA2757764C (en) 2018-03-13
US20160176939A1 (en) 2016-06-23
NZ595707A (en) 2013-05-31
KR101785738B1 (ko) 2017-10-17
AR076349A1 (es) 2011-06-01
SG175178A1 (en) 2011-11-28
US20120045465A1 (en) 2012-02-23
CN105622749A (zh) 2016-06-01
US10759840B2 (en) 2020-09-01
TWI517859B (zh) 2016-01-21
US20210107957A1 (en) 2021-04-15
ZA201108336B (en) 2012-08-29
IL215668A0 (en) 2012-01-31
JPWO2010123065A1 (ja) 2012-10-25
US11732018B2 (en) 2023-08-22
CN102803487A (zh) 2012-11-28
US20180170986A1 (en) 2018-06-21
CO6470802A2 (es) 2012-06-29
BRPI1014998A2 (pt) 2016-04-26
AU2010240099B2 (en) 2015-01-15
IL228948A0 (en) 2013-12-31
ES2528766T3 (es) 2015-02-12
US9266932B2 (en) 2016-02-23
AU2010240099A1 (en) 2011-11-03
KR20120030380A (ko) 2012-03-28
DK2423310T3 (en) 2015-02-02
HK1167427A1 (en) 2012-11-30
KR20170046192A (ko) 2017-04-28
CN102803487B (zh) 2016-01-20
TW201041593A (en) 2010-12-01
EP2423310A1 (en) 2012-02-29
WO2010123065A1 (ja) 2010-10-28
JP5730191B2 (ja) 2015-06-03
EP2423310B1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
MX2011011132A (es) Peptido auxiliar del antigeno del cancer.
CY1122691T1 (el) Πρωτεϊνες δεσμευσης αλβουμινης ορου
HUE042053T2 (hu) Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
MX359680B (es) Vacunas peptídicas para cánceres que expresan antígenos hig2 asociados con tumores.
CY1120471T1 (el) Αντισωματα κατα του cd70
MX364777B (es) Péptidos cancerígenos universales derivados de telomerasa.
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
MX2009007008A (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo.
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CR20200409A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027).
CO6351750A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
MX358249B (es) Proteínas de enlace al antígeno il-23 humanas.
EP2228072A4 (en) CANCER VACCINE COMPOSITION
MX2014005108A (es) Constructos de polipeptidos y sus usos.
CY1116700T1 (el) Παρασκευη συνθετικου χολικου οξεος
MX337873B (es) Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
CO6690759A2 (es) Anticuerpos, fragmentos de unión o derivados de los mismos que se unen específicamente a la proteína 4-1 bb
GT201200271A (es) Proteínas que se unen al tnf-a
CL2012003187A1 (es) Proteinas de union a il-1 beta humana y ala il-1 alfa humana; conjugado de dicha proteina de unión; composicion para la liberacion de una proteina de unión; composicion farmaceutica.
PE20141658A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
MX355074B (es) Inmunoterapia novedosa contra varios tumores incluidos el cancer gastrico y gastrointestinal.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal